In this blog post, we summarize the latest developments in computational methods for High Content Screening (HCS) data analysis. Specifically, we discuss how artificial intelligence (AI) and machine learning (ML) approaches enhance data processing, quality control and feature extraction to support drug discovery and development.
Table of Contents:
- High Content Screening (HCS) in Drug Discovery
- What Is Cell Painting?
- How Can AI Aid in High Content Screening Data Analysis?
- Using AI for Phenotypic Drug Discovery
High Content Screening (HCS) in Drug Discovery
High Content Screening (HCS) is an imaging and quantification method that enables simultaneous evaluation of multiple cellular and molecular features and supports unbiased phenotypic screening, making it a valuable tool for drug discovery and development. The advances in cell imaging and computational image analysis methods have propelled the field forward over the last decade and enabled research and clinical insights. Today, artificial intelligence (AI) and machine learning (ML) are further expanding the capabilities of this approach to accelerate drug discovery and development.
One of the main advantages of HCS is the ability to test potential drug candidates directly in living systems that mimic disease states. Such information-rich data facilitates comprehensive assessment of the effect of active molecules on cells and produces insights relevant to clinical outcomes. HCS can be used across many steps of the drug discovery pipeline, including early stages of discovery, lead optimization and target validation, as well as in toxicity assessment, drug repurposing and basic research. HCS enables researchers to screen thousands of active compounds in a single experiment. It can help identify potential targets of therapeutic intervention, as well as elucidate the modes and mechanisms of action of drug compounds. In toxicity screening, HCS can be used to detect adverse effects on cell viability and function.
While HCS is a powerful approach, the method is not without challenges and limitations. The sheer size and complexity of HCS data presents a big hurdle for deconvoluting and extracting insights from screening datasets. Custom assays take a long time to develop, and the output requires sophisticated data analysis methods that are difficult to automate and generalize. Variation in imaging methods, as well as biological variability and complexity also contribute to the challenges of HCS application. ML approaches solve many of these challenges and unlock the insights in HCS data by enhancing quality control (QC), facilitating feature extraction and introducing multimodal capabilities for better predictions.